3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Sarcoma, Ewing
3
Sarcoma
3
Sarcoma, Clear Cell
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Liposarcoma
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Wilms Tumor
1
Vascular Neoplasms
1
Teratoma
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Recurrence
1
Pleuropulmonary blastoma
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms, Adipose Tissue
1
Myoepithelioma
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
9
fludarabine
7
Dexamethasone
7
pomalidomide
6
Rituximab
6
pembrolizumab
5
selinexor
4
obinutuzumab
4
glofitamab
4
Lenalidomide
4
daratumumab
3
belantamab mafodotin
3
Temozolomide
3
Gemcitabine
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
fludarabine phosphate
2
enzalutamide
2
cemiplimab
2
carfilzomib
2
abemaciclib
2
PF06821497
2
Mesna
2
Lisaftoclax
2
Injections
2
Immunotherapy, Adoptive
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Ifosfamide
×
30 days
×
Clear all
NCT05533775
2026-05-04
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2
Recruiting
65 enrolled